Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M288443-5mg | 5mg | In stock | $195.90 | |
M288443-10mg | 10mg | In stock | $271.90 | |
M288443-25mg | 25mg | In stock | $597.90 | |
M288443-50mg | 50mg | In stock | $1,033.90 | |
M288443-100mg | 100mg | In stock | $1,305.90 |
BRS-3 antagonist; also GRPR agonist
Specifications & Purity | Moligand™, ≥98%(HPLC) |
---|---|
Biochemical and Physiological Mechanisms | Bombesin receptor subtype 3 (BRS-3) antagonist (IC50= 4.8μM). Also binds GRPR (IC50= 16μM). InhibitsBA1-stimulated cytosolic Ca2+and suppresses cell proliferation in a lung cancer modelin vitro. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of BB 3 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2S)-3-(1H-indol-3-yl)-N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-2-[(4-nitrophenyl)carbamoylamino]propanamide |
---|---|
INCHI | InChI=1S/C32H35N5O5/c1-42-26-15-9-23(10-16-26)32(17-5-2-6-18-32)21-34-30(38)29(19-22-20-33-28-8-4-3-7-27(22)28)36-31(39)35-24-11-13-25(14-12-24)37(40)41/h3-4,7-16,20,29,33H,2,5-6,17-19,21H2,1H3,(H,34,38)(H2,35,36,39)/t29-/m0/s1 |
InChi Key | JOKVJNCYOSFDGC-LJAQVGFWSA-N |
Canonical SMILES | COC1=CC=C(C=C1)C2(CCCCC2)CNC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-] |
Isomeric SMILES | COC1=CC=C(C=C1)C2(CCCCC2)CNC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)NC5=CC=C(C=C5)[N+](=O)[O-] |
PubChem CID | 91827363 |
Molecular Weight | 569.65 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2224530 | Certificate of Analysis | Jul 21, 2022 | M288443 |
I2224531 | Certificate of Analysis | Jul 21, 2022 | M288443 |
I2224532 | Certificate of Analysis | Jul 21, 2022 | M288443 |
I2224533 | Certificate of Analysis | Jul 21, 2022 | M288443 |
I2224534 | Certificate of Analysis | Jul 21, 2022 | M288443 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 56.97, Max Conc. mM: 100 |
---|
1. Moody TW, Mantey SA, Moreno P, Nakamura T, Lacivita E, Leopoldo M, Jensen RT. (2015) ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.. Peptides, 64 (13): (55-61). [PMID:25554218] [10.1021/op500134e] |